"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02068820","Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG",,"Completed","Has Results","Endometrial Cancer","Device: ISB dye and standard white light imaging|Device: ICG dye and FireFly fluorescence imaging","Number of Pelvic Sentinel Lymph Nodes (SLN) in Endometrial Cancer Patients Detected by Either ICG and/or ISB Dyes.|Negative Predictive Value (NPV) of Pelvic SLN in Endometrial Cancer in Relation to the Number of Nodes With Metastasis.","AdventHealth","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SLN Mapping","September 2012","January 2015","January 2015","February 21, 2014","September 10, 2019","September 10, 2019","Florida Hospital Gynecologic Oncology, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02068820"
2,"NCT02209532","A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping","FILM","Completed","Has Results","Endometrial Cancer|Uterine Cancer|Cervical Cancer","Device: PINPOINT","Effectiveness of PINPOINT and IC2000 in the Identification of Lymph Nodes Defined as the Proportion of Confirmed Lymph Nodes Identified|Effectiveness of PINPOINT and Blue Dye in the Identification of at Least One Lymph Node Defined as the Number of Subjects in Which at Least One Confirmed Lymph Node Was Identified With Either PINPOINT or Blue Dye|Effectiveness of PINPOINT and Blue Dye in the Identification of Bilateral Lymph Nodes Defined as the Number of Subjects in Which Lymph Nodes Were Identified Bilaterally With Either PINPOINT or Blue Dye.|Identification of Lymph Nodes Following Lymphatic Channels Defined as the Number of Subjects in Which Confirmed Lymph Nodes Were Identified by Following a Lymphatic Channel With Either PINPOINT or Blue Dye.|Safety of Interstitial Injection of ICG Defined as the Number of Adverse Effects Related to ICG|Anatomic Distribution of Lymph Nodes","Novadaq Technologies ULC, now a part of Stryker","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PP LNM 01","December 2015","June 2017","June 2017","August 6, 2014","March 25, 2019","March 25, 2019","O'Connor Hospital, San Jose, California, United States|Lee Memorial Hospital, Fort Myers, Florida, United States|Memorial Sloan Kettering, New York, New York, United States|Duke Cancer Institute, Durham, North Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|CHU de Québec - Université Laval, Quebec City, Quebec, Canada|Hospital HIMA San Pablo, Caguas, Puerto Rico","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02209532/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02209532"
3,"NCT01818739","Lymph Node Mapping in Patients With Endometrial Cancer",,"Completed","Has Results","Endometrial Cancer","Procedure: sentinel lymph node detection|Drug: indocyanine green solution|Drug: isosulfan blue|Procedure: sentinel lymph node biopsy","Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease|Percentage of Metastatic Cases Found Using Ultra-sectioning and IHC Staining","Ohio State University Comprehensive Cancer Center","Female","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","204","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","OSU-12114|NCI-2013-00530","March 2013","November 16, 2016","March 31, 2017","March 26, 2013","June 22, 2021","June 22, 2021","Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT01818739"
4,"NCT01898403","Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma",,"Completed","Has Results","Recurrent Melanoma","Drug: Indocyanine green solution|Drug: Isosulfan blue (ISB)|Diagnostic Test: Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)","Sentinel Lymph Nodes (SLN) Mapping","Stanford University|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-27319|NCI-2013-01286|MEL0010|P30CA124435","June 2013","June 2014","April 2015","July 12, 2013","May 24, 2017","May 24, 2017","Stanford University Hospitals and Clinics, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01898403"
5,"NCT01662752","Lymphatic Mapping for Sentinel Node Identification and Analysis",,"Completed","Has Results","Colorectal Cancer","Drug: Indocyanine green","Subjects in Which the SLN(s) Are Identified|Sensitivity and Specificity of Tumour-bearing Status of SLN(s) as a Measure of Lymph Node Status When Assessed by Standard Techniques","Imperial College London|London North West Healthcare NHS Trust","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","C/32/2012","May 2013","September 2015","October 2015","August 10, 2012","August 9, 2019","August 9, 2019","North West London Hospital, London, UK, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01662752"
6,"NCT01673022","Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging","FIRES","Completed","Has Results","Endometrial Cancer|Cervical Cancer","Drug: IC Green","Estimate the Sensitivity of the Sentinel Lymph Node","Indiana University","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","430","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","1204008493","May 2012","January 2017","January 2017","August 27, 2012","July 24, 2018","July 24, 2018","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Indiana University, Indianapolis, Indiana, United States|St. Elizabeth Healthcare, Edgewood, Kentucky, United States|Sunrise Hospital and Medical Center, Las Vegas, Nevada, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Tri Health Good Smaritan Hospital, Cincinnati, Ohio, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01673022"
7,"NCT02419807","Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer",,"Completed","Has Results","Stage I Breast Cancer|Stage II Breast Cancer","Drug: Indocyanine Green Solution|Radiation: Technetium Tc-99m Sulfur Colloid|Procedure: Lymphoscintigraphy|Procedure: Axillary Lymph Node Biopsy","Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods","Case Comprehensive Cancer Center|National Cancer Institute (NCI)|Mitaka USA, Inc.","Female","Child, Adult, Older Adult","Not Applicable","102","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CASE10114","February 17, 2015","February 2019","February 2019","April 17, 2015","October 22, 2020","November 16, 2020","Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02419807"
8,"NCT01771666","Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer",,"Completed","Has Results","Breast Cancer","Device: SPY Elite Imaging|Drug: Indocyanine Green|Drug: Isosulfan blue|Drug: 99technetium-sulfur colloid radiolabel","Agreement of Labeling Between Isosulfan Blue (IS-BLUE) and Indocyanine Green (IC-GREEN)|Detection of Indocyanine Green (IC-GREEN); Isosulfan Blue (IS-BLUE); and 99technetium-sulfur Colloid Radiolabel in Resected Sentinel Nodes","Stanford University","Female","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","23","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","IRB-21030|SU-06122012-10130|BRS0022","July 2012","March 17, 2015","March 17, 2015","January 18, 2013","December 11, 2017","December 11, 2017","Stanford University, School of Medicine, Stanford, California, United States",,"https://ClinicalTrials.gov/show/NCT01771666"
